Abbott Laboratories has shown strong performance in the US medical device sector in the first half of 2025, with steady growth in its core product lines. According to GlobalData, a leading data and analytics company, Abbott’s top revenue product lines have maintained consistent average selling prices (ASPs) from 2024 to 2025, indicating resilience to economic pressures such as evolving tariff policies.
While some of Abbott’s high-volume product lines experienced a decline in ASPs in the first half of 2025 compared to the same period last year, the company’s highest-volume products in 2024 saw modest increases in ASPs. This shift in ASPs may be attributed to changing purchasing strategies among US healthcare facilities, possibly influenced by shifting public health priorities and cost considerations.
Abbott reported a strong first half in 2025, with a 14.8% growth in US medical device sales compared to the first half of 2024. Key product lines like MitraClip, Ensite X, and Tactiflex continue to perform well, contributing to Abbott’s success in the US cardiovascular market, where the company holds approximately 18% market share according to GlobalData.
However, Abbott’s US diagnostics segment experienced a slight decline in year-over-year sales in the second quarter of 2025, particularly in point-of-care and rapid diagnostics. This dip in sales can be attributed to reduced demand for Covid-19 testing, which had previously driven high sales volumes. The changing demand landscape in diagnostics may have impacted Abbott’s high-volume sales in this segment.
Overall, Abbott Laboratories remains a strong player in the US medical device sector, with a diverse product portfolio and a resilient market position. The company’s ability to adapt to changing market dynamics and maintain consistent performance in key product lines bodes well for its future growth and success in the industry.
